TOVX Theriva Biologics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: TOVX
Price (delayed)
$0.2733
Market cap
$2.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.85
Enterprise value
-$6.65M
Relative Growth:
Rel. Growth:
20
Relative Strength:
Rel. Strength:
1
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
2
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's
Highlights
Theriva Biologics's EPS has soared by 84% YoY and by 64% from the previous quarter
The quick ratio has plunged by 60% YoY and by 21% from the previous quarter
TOVX's equity has plunged by 59% YoY and by 31% from the previous quarter
Key stats
What are the main financial stats of TOVX
Market
Valuations
Earnings
Shares outstanding
9.6M
Market cap
$2.62M
Enterprise value
-$6.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$30.02M
Net income
-$29.56M
EBIT
-$29.56M
EBITDA
-$28.94M
Free cash flow
-$18.09M
Per share
Balance sheet
Liquidity
EPS
-$4.85
EPS diluted
-$4.85
Free cash flow per share
-$2.68
Book value per share
$1.3
Revenue per share
$0
TBVPS
$5.31
Total assets
$35.83M
Total liabilities
$25.21M
Debt
$2.89M
Equity
$10.62M
Working capital
$2.35M
Debt to equity
0.27
Current ratio
1.19
Quick ratio
0.98
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.4%
Return on equity
-169.3%
Return on invested capital
-177.6%
Return on capital employed
-126.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TOVX stock price
How has the Theriva Biologics stock price performed over time
Intraday
-7.7%
1 week
-15.65%
1 month
-33.33%
1 year
-86.13%
YTD
-84.38%
QTD
-32.54%
Financial performance
How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.02M
Net income
-$29.56M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 33% YoY and by 19% QoQ
The company's operating income fell by 23% YoY and by 18% QoQ
Price vs fundamentals
How does TOVX's price correlate with its fundamentals
Growth
What is Theriva Biologics's growth rate over time
Valuation
What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has soared by 84% YoY and by 64% from the previous quarter
TOVX's equity has plunged by 59% YoY and by 31% from the previous quarter
TOVX's P/B is 43% below its 5-year quarterly average of 0.4 but 15% above its last 4 quarters average of 0.2
Efficiency
How efficient is Theriva Biologics business performance
The ROE has shrunk by 157% YoY and by 45% QoQ
The ROA has plunged by 93% YoY and by 24% from the previous quarter
The return on invested capital has dropped by 53% year-on-year and by 28% since the previous quarter
Dividends
What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TOVX.
Financial health
How did Theriva Biologics financials performed over time
The total assets is 42% more than the total liabilities
Theriva Biologics's total liabilities has soared by 71% YoY and by 51% from the previous quarter
The quick ratio has plunged by 60% YoY and by 21% from the previous quarter
The debt is 73% smaller than the equity
TOVX's equity has plunged by 59% YoY and by 31% from the previous quarter
The debt has soared by 58% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.